C-ray is dedicated to building a leading platform in the field of radiopharmaceuticals in China

C-Ray Therapeutics is an innovative biopharmaceutical company specialized in the development, manufacturing, clinical application and commercialization of radiopharmaceuticals. Since incubated by leading investors in 2021, the company has built a team of experts possessing deep expertise in radiochemistry, the application of nuclear technology, biology, medicine, pharmacology, and operations management. The company is dedicated to building innovative technology platforms, emerging technologies and the commercialization of advanced radiopharmaceuticals from China and around the world.

C-Ray Therapeutics aims to become a world-leader in radiopharmaceuticals by acquiring some of the world’s most advanced radiopharmaceutical candidates and technology platforms; and developing its in-house capabilities in the discovery, development, and commercialization of novel radiopharmaceuticals.

In 2021, the company began to build the its R&D and Manufacturing Center in Wenjiang district of Chengdu. This world-class facility, once completed, will become a R&D and manufacturing site equipped with advanced production equipments and supporting facilities enabling the clinical and commercialization stage manufacturing of innovative radiopharmaceuticals, effectively promoting the technological and product developments in the industry.

In the future, C-Ray Therapeutics will adopt a portfolio strategy focused on patients’ unmet needs and life-threatening diseases such as oncology to provide Chinese doctors and patients with integrated radio pharmaceutical-based diagnostic and treatment solutions.